American Shared Hospital Services (AMS) 10-Q 10 Aug 17 2017 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 07, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Entity Registrant Name	AMERICAN SHARED HOSPITAL SERVICES
Entity Central Index Key	744,825
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	AMS
Entity Common Stock, Shares Outstanding		5,710,000

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 2,601,000	$ 2,871,000
Restricted cash	250,000	250,000
Accounts receivable, net of allowance for doubtful accounts of $100,000 at June 30, 2017 and $100,000 at December 31, 2016	4,913,000	4,085,000
Other receivables	185,000	290,000
Prepaid expenses and other current assets	896,000	892,000
Total current assets	8,845,000	8,388,000
Property and equipment:
Medical equipment and facilities	93,865,000	96,270,000
Office equipment	542,000	537,000
Deposits and construction in progress	7,209,000	8,073,000
Property and equipment	101,616,000	104,880,000
Accumulated depreciation and amortization	(52,311,000)	(53,549,000)
Net property and equipment	49,305,000	51,331,000
Investment in equity securities	579,000	579,000
Other assets	265,000	300,000
Total assets	58,994,000	60,598,000
Current liabilities:
Accounts payable	206,000	319,000
Employee compensation and benefits	202,000	184,000
Other accrued liabilities	1,225,000	1,100,000
Current portion of long-term debt	2,347,000	2,205,000
Current portion of obligations under capital leases	4,467,000	4,873,000
Total current liabilities	8,447,000	8,681,000
Long-term debt, less current portion	4,802,000	5,106,000
Long-term capital leases, less current portion	12,563,000	14,852,000
Deferred revenue, less current portion	557,000	610,000
Deferred income taxes	4,542,000	4,176,000
Shareholders' equity:
Common stock (10,000,000 authorized; 5,710,000 shares issued and outstanding at June 30, 2017 and 5,468,000 shares at December 31, 2016)	10,711,000	10,596,000
Additional paid-in capital	6,049,000	5,949,000
Retained earnings	5,356,000	4,950,000
Total equity-American Shared Hospital Services	22,116,000	21,495,000
Non-controlling interest in subsidiaries	5,967,000	5,678,000
Total shareholders' equity	28,083,000	27,173,000
Total liabilities and shareholders' equity	$ 58,994,000	$ 60,598,000

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Allowance for doubtful accounts (in dollars)	$ 100,000	$ 100,000
Common stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	5,710,000	5,468,000
Common stock, shares outstanding	5,710,000	5,468,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Medical services revenue	$ 4,945,000	$ 4,518,000	$ 9,859,000	$ 8,756,000
Costs of revenue:
Maintenance and supplies	248,000	250,000	480,000	494,000
Depreciation and amortization	1,722,000	1,649,000	3,326,000	3,211,000
Other direct operating costs	724,000	780,000	1,456,000	1,479,000
Costs of revenue	2,694,000	2,679,000	5,262,000	5,184,000
Gross Margin	2,251,000	1,839,000	4,597,000	3,572,000
Selling and administrative expense	1,138,000	963,000	2,277,000	1,912,000
Interest expense	444,000	433,000	897,000	718,000
Operating income	669,000	443,000	1,423,000	942,000
(Loss) on early extinguishment of debt	0	0	0	(108,000)
Interest and other (loss) income	(5,000)	3,000	(1,000)	8,000
Income before income taxes	664,000	446,000	1,422,000	842,000
Income tax expense	220,000	93,000	436,000	157,000
Net income	444,000	353,000	986,000	685,000
Less: Net (income) attributable to non-controlling interests	(331,000)	(260,000)	(580,000)	(541,000)
Net income attributable to American Shared Hospital Services	$ 113,000	$ 93,000	$ 406,000	$ 144,000
Net income per share:
Earnings per common share - basic	$ 0.02	$ 0.02	$ 0.07	$ 0.03
Earnings per common share - diluted	$ 0.02	$ 0.02	$ 0.07	$ 0.03

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Sub-Total ASHS [Member]	Non-controlling Interest [Member]
Balances at Dec. 31, 2015	$ 25,180,000	$ 10,376,000	$ 5,734,000	$ 4,020,000	$ 20,130,000	$ 5,050,000
Balances (in shares) at Dec. 31, 2015		5,364,000
Stock-based compensation expense	215,000	$ 0	215,000	0	215,000	0
Stock-based compensation expense (in shares)		4,000
Warrants exercised	220,000	$ 220,000	0	0	220,000	0
Warrants exercised (in shares)		100,000
Non-controlling interest investment in subsidiaries	7,000	$ 0	0	0	0	7,000
Cash distributions to non-controlling interests	(699,000)	0	0	0	0	(699,000)
Net income	2,250,000	0	0	930,000	930,000	1,320,000
Balances at Dec. 31, 2016	27,173,000	$ 10,596,000	5,949,000	4,950,000	21,495,000	5,678,000
Balances (in shares) at Dec. 31, 2016		5,468,000
Stock-based compensation expense	100,000	$ 0	100,000	0	100,000	0
Stock-based compensation expense (in shares)		4,000
Restricted Stock	0	$ 0	0	0	0	0
Restricted Stock (in shares)		162,000
Warrants and options exercised	115,000	$ 115,000	0	0	115,000	0
Warrants and options exercised (in shares)		76,000
Cash distributions to non-controlling interests	(291,000)	$ 0	0	0	0	(291,000)
Net income	986,000	0	0	406,000	406,000	580,000
Balances at Jun. 30, 2017	$ 28,083,000	$ 10,711,000	$ 6,049,000	$ 5,356,000	$ 22,116,000	$ 5,967,000
Balances (in shares) at Jun. 30, 2017		5,710,000

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Operating activities:
Net income	$ 986,000	$ 685,000
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	3,364,000	3,234,000
Loss (gain) on sale of assets	6,000	(1,000)
Loss on early extinguishment of debt	0	108,000
Deferred income tax	366,000	176,000
Stock-based compensation expense	100,000	119,000
Net accrued interest on lease financing	(53,000)	0
Other non-cash items	0	4,000
Changes in operating assets and liabilities:
Receivables	(723,000)	(767,000)
Prepaid expenses and other assets	15,000	(262,000)
Customer deposits/deferred revenue	(57,000)	(108,000)
Accounts payable and accrued liabilities	34,000	213,000
Net cash from operating activities	4,038,000	3,401,000
Investing activities:
Payment for purchase of property and equipment	(1,469,000)	(575,000)
Proceeds from sale of equipment	150,000	0
Net cash (used in) investing activities	(1,319,000)	(575,000)
Financing activities:
Principal payments on long-term debt	(1,163,000)	(2,059,000)
Principal payments on capital leases	(2,642,000)	(2,055,000)
Proceeds from long-term debt financing on property and equipment	992,000	0
Capital contributions from non-controlling interests	0	7,000
Distributions to non-controlling interests	(291,000)	(301,000)
Proceeds from warrants and options exercised	115,000	1,137,000
Net cash (used in) financing activities	(2,989,000)	(3,271,000)
Net change in cash and cash equivalents	(270,000)	(445,000)
Cash and cash equivalents at beginning of period	2,871,000	2,209,000
Cash and cash equivalents at end of period	2,601,000	1,764,000
Supplemental cash flow disclosure:
Interest	978,000	1,066,000
Income taxes paid	30,000	97,000
Schedule of non-cash investing and financing activities
Acquisition of equipment with capital lease financing	$ 0	$ 7,401,000

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Basis of Presentation In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to present fairly American Shared Hospital Services’ consolidated financial position as of June 30, 2017 and the results of its operations for the three and six month periods ended June 30, 2017 and 2016, which results are not necessarily indicative of results on an annualized basis. Consolidated balance sheet amounts as of December 31, 2016 have been derived from audited consolidated financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2016 included in the Company’s 10-K filed with the Securities and Exchange Commission. These consolidated financial statements include the accounts of American Shared Hospital Services and its subsidiaries (the “Company”) as follows: the Company wholly-owns the subsidiaries American Shared Radiosurgery Services (“ASRS”), PBRT Orlando, LLC (“Orlando”), OR21, Inc. (“OR21”), and MedLeader.com, Inc. (“MedLeader”); the Company is the majority owner of Long Beach Equipment, LLC (“LBE”); ASRS is the majority-owner of GK Financing, LLC (“GKF”) which wholly-owns the subsidiaries Instituto de Gamma Knife del Pacifico S.A.C. (“GKPeru”) and GK Financing U.K., Limited (“GKUK”); GKF is the majority owner of the subsidiaries Albuquerque GK Equipment, LLC (“AGKE”) and Jacksonville GK Equipment, LLC (“JGKE”). The Company (through ASRS) and Elekta AB, the manufacturer of the Gamma Knife (through its wholly-owned United States subsidiary, GKV Investments, Inc.), entered into an operating agreement and formed GK Financing, LLC. As of June 30, 2017, GKF provided Gamma Knife units to sixteen medical centers in the United States in the states of Arkansas, California, Florida, Illinois, Massachusetts, Mississippi, Nevada, New Jersey, New Mexico, New York, Tennessee, Oklahoma, Ohio, Oregon, and Texas. The Company through its wholly-owned subsidiary, Orlando, provided proton beam radiation therapy (“PBRT”) and related equipment to a customer in the United States. The Company also directly provides radiation therapy and related equipment, including Intensity Modulated Radiation Therapy (“IMRT”), Image Guided Radiation Therapy (“IGRT”) and a CT Simulator to the radiation therapy department at an existing Gamma Knife site in Massachusetts. The Company formed the subsidiaries GKPeru and GKUK for the purposes of expanding its business internationally into Peru and the United Kingdom, respectively; Orlando and LBE to provide proton beam therapy services in Orlando, Florida and Long Beach, California; and AGKE and JGKE to provide Gamma Knife services in Albuquerque, New Mexico and Jacksonville, Florida, respectively. AGKE began operations in the second quarter of 2011 and JGKE began operations in the fourth quarter of 2011. Orlando treated its first patient in April 2016. GKPeru treated its first patient in July 2017. GKUK is inactive and LBE is not expected to generate revenue within the next two years. The Company continues to develop its design and business model for “The Operating Room for the 21st Century” SM SM 50 50 MedLeader was formed to provide continuing medical education online and through videos for doctors, nurses, and other healthcare workers. This subsidiary is not operational at this time. All significant intercompany accounts and transactions have been eliminated in consolidation. Based on the guidance provided in accordance with Accounting Standards Codification (“ASC”) 280 Segment Reporting In February 2016, the Company used proceeds from the lease financing of its MEVION S250 at Orlando Health – UF Health Cancer Center (“Orlando Health”) to pay down $ 1,000,000 Extinguishment of Liabilities Debt Modifications and Extinguishments 108,000 145,000 80,000 28,000 As of December 31, 2016, the Company had warrants outstanding representing the right to purchase 100,000 2.20 50,000 100,000 25,000 In April 2017, an existing customer exercised their option to purchase the Gamma Knife unit at its hospital at the end of the lease term for a predetermined purchase price, pursuant to the lease agreement. The lease terminated in April 2017, at which time, the unit was depreciated to the purchase price of the sale. Based on the guidance provided in ASC 360 Property, Plant and Equipment On July 21, 2017, the Company entered into a Maintenance and Support Agreement (the “Mevion Service Agreement”) with Mevion Medical Systems, Inc. (“Mevion”), formerly Still River Systems, which provides for maintenance and support of the Company’s PBRT unit at Orlando Health. The Mevion Service Agreement begins September 5, 2017 and required an upfront payment of $ 1,000,000 In May 2014, the Financial Accounting Standards Board “(FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers Technical Corrections and Improvements to Topic 606, In January 2016, the FASB issued ASU No. 2016-01 Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02 Leases In March 2016, the FASB issued ASU No. 2016-09 Compensation – Stock Compensation In June 2016, the FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2016, the FASB issued ASU No. 2016-15 Statement of Cash Flows (Topic 230) – Classification of Certain Cash Receipts and Cash Payments In November 2016, the FASB issued ASU No. 2016-18 Statement of Cash Flows (Topic 230) – Restricted Cash In May 2017, the FASB issued ASU No. 2017-09 Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting

Per Share Amounts

Per Share Amounts	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 2. Per Share Amounts Per share information has been computed based on the weighted average number of common shares and dilutive common share equivalents outstanding. The computation for the three and six month periods ended June 30, 2017 included all of the Company’s outstanding stock options because the exercise price of the options was lower than the average market price during those periods. The computation for the three and six month periods ended June 30, 2016 excluded approximately 605,000 and 627,000 of the Company’s stock options, respectively, because the exercise price of the options was higher than the average market price during those periods. Based on the guidance provided in accordance with ASC 260 Earnings Per Share The following table sets forth the computation of basic and diluted earnings per share for the three and six month periods ended June 30, 2017 and 2016: Three months ended June 30, Six months ended June 30, 2017 2016 2017 2016 Net income attributable to American Shared Hospital Services $ 113,000 $ 93,000 $ 406,000 $ 144,000 Weighted average common shares for basic earnings per share 5,935,000 5,552,000 5,725,000 5,548,000 Diluted effect of stock options and restricted stock 208,000 16,000 196,000 16,000 Weighted average common shares for diluted earnings per share 6,143,000 5,568,000 5,921,000 5,564,000 Basic earnings per share $ 0.02 $ 0.02 $ 0.07 $ 0.03 Diluted earnings per share $ 0.02 $ 0.02 $ 0.07 $ 0.03

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 3. Stock-based Compensation In June 2010, the Company’s shareholders approved an amendment and restatement of the Company’s stock incentive plan, renaming it the Incentive Compensation Plan (the “Plan”), and among other things, increasing the number of shares of the Company’s common stock reserved for issuance under the Plan to 1,630,000 Stock-based compensation expense associated with the Company’s stock-based options to employees is calculated using the Black-Scholes valuation model. The Company’s stock-based awards have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair value estimates. The estimated fair value of the Company’s option grants is estimated using assumptions for expected life, volatility, dividend yield, and risk-free interest rate which are specific to each award. The estimated fair value of the Company’s options is amortized over the period during which an employee is required to provide service in exchange for the award (requisite service period), usually the vesting period. Accordingly, stock-based compensation cost before income tax effect for the Company’s options and restricted stock awards, in the amount of $ 50,000 100,000 60,000 119,000 358,000 On January 4, 2017, the Company entered into a Performance Share Award Agreement with three executive officers of the Company (the “Award Agreements”) for 161,766 Stock Compensation 542,000 Grant Date Restricted Weighted- Stock Average Fair Intrinsic Awards/Units Value Value Outstanding at January 1, 2017 4,000 $ 2.25 $ - Granted 21,000 $ 3.48 $ - Vested (13,000) $ 3.07 $ - Forfeited - $ - $ - Outstanding at June 30, 2017 12,000 $ 3.54 $ 4,000 Weighted- Grant Date Average Weighted- Remaining Average Contractual Stock Exercise Life (in Intrinsic Options Price Years) Value Outstanding at January 1, 2017 625,000 $ 2.85 4.25 $ - Granted 14,000 $ 3.90 - $ - Exercised (4,000) $ 2.81 - $ - Forfeited (23,000) $ 2.82 - $ - Outstanding at June 30, 2017 612,000 $ 2.87 3.85 $ 630,000 Exercisable at June 30, 2017 295,000 $ 2.82 3.63 $ 318,000

Investment in Equity Securities

Investment in Equity Securities	6 Months Ended
	Jun. 30, 2017
Investments, All Other Investments [Abstract]
Cost-method Investments, Description	Note 4. Investment in Equity Securities As of June 30, 2017 and December 31, 2016, the Company had a $ 579,000 0.46 The Company reviewed this investment at June 30, 2017 in light of both current market conditions and the current operations of Mevion as they continue to grow their PBRT business. Based on its analysis, the Company determined no additional impairment needed to be recognized as of June 30, 2017.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 5. Fair Value of Financial Instruments The Company’s disclosures of the fair value of financial instruments is based on a fair value hierarchy that prioritizes the inputs to the valuation techniques used to measure fair value into three levels. Level 1 inputs are unadjusted quoted market prices in active markets for identical assets and liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for assets or liabilities, and reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the asset or liability. Level 1 Level 2 Level 3 Total Carrying Value June 30, 2017 Assets: Cash, cash equivalents, restricted cash $ 2,851 $ - $ - $ 2,851 $ 2,851 Investment in equity securities - - 579 579 579 Total $ 2,851 $ - $ 579 $ 3,430 $ 3,430 Liabilities: Debt obligations $ - $ - $ 7,236 $ 7,236 $ 7,149 Total $ - $ - $ 7,236 $ 7,236 $ 7,149 December 31, 2016 Assets: Cash, cash equivalents, restricted cash $ 3,121 $ - $ - $ 3,121 $ 3,121 Investment in equity securities - - 579 579 579 Total $ 3,121 $ - $ 579 $ 3,700 $ 3,700 Liabilities: Debt obligations $ - $ - $ 7,354 $ 7,354 $ 7,311 Total $ - $ - $ 7,354 $ 7,354 $ 7,311

Repurchase of Common Stock

Repurchase of Common Stock	6 Months Ended
	Jun. 30, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 6. Repurchase of Common Stock In 1999 and 2001, the Board of Directors approved resolutions authorizing the Company to repurchase up to a total of 1,000,000 72,000

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 7. Income Taxes The Company generally calculates its effective income tax rate at the end of an interim period using an estimate of the annualized effective income tax rate expected to be applicable for the full fiscal year. However, when a reliable estimate of the annualized effective income tax rate cannot be made, the Company computes its provision for income taxes using the actual effective income tax rate for the results of operations reported within the year-to-date periods. The Company’s effective income tax rate is highly influenced by relative income or losses reported and the amount of the nondeductible stock-based compensation associated with grants of its common stock options and historically from the results of foreign operations. A small change in estimated annual pretax income (loss) can produce a significant variance in the annualized effective income tax rate given the expected amount of these items. As a result, the Company has computed its provision for income taxes for the three and six month periods ended June 30, 2017 and 2016 by applying the actual effective tax rates to income or (loss) reported within the condensed consolidated financial statements through those periods.

Per Share Amounts (Tables)

Per Share Amounts (Tables)	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table sets forth the computation of basic and diluted earnings per share for the three and six month periods ended June 30, 2017 and 2016: Three months ended June 30, Six months ended June 30, 2017 2016 2017 2016 Net income attributable to American Shared Hospital Services $ 113,000 $ 93,000 $ 406,000 $ 144,000 Weighted average common shares for basic earnings per share 5,935,000 5,552,000 5,725,000 5,548,000 Diluted effect of stock options and restricted stock 208,000 16,000 196,000 16,000 Weighted average common shares for diluted earnings per share 6,143,000 5,568,000 5,921,000 5,564,000 Basic earnings per share $ 0.02 $ 0.02 $ 0.07 $ 0.03 Diluted earnings per share $ 0.02 $ 0.02 $ 0.07 $ 0.03

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	The following table summarizes the outstanding restricted stock awards, consisting primarily of annual automatic grants and deferred compensation to non-employee directors, for the six month period ended June 30, 2017: Grant Date Restricted Weighted- Stock Average Fair Intrinsic Awards/Units Value Value Outstanding at January 1, 2017 4,000 $ 2.25 $ - Granted 21,000 $ 3.48 $ - Vested (13,000) $ 3.07 $ - Forfeited - $ - $ - Outstanding at June 30, 2017 12,000 $ 3.54 $ 4,000
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes stock option activity for the six month period ended June 30, 2017: Weighted- Grant Date Average Weighted- Remaining Average Contractual Stock Exercise Life (in Intrinsic Options Price Years) Value Outstanding at January 1, 2017 625,000 $ 2.85 4.25 $ - Granted 14,000 $ 3.90 - $ - Exercised (4,000) $ 2.81 - $ - Forfeited (23,000) $ 2.82 - $ - Outstanding at June 30, 2017 612,000 $ 2.87 3.85 $ 630,000 Exercisable at June 30, 2017 295,000 $ 2.82 3.63 $ 318,000

Fair Value of Financial Instr16

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The estimated fair value of the Company’s assets and liabilities as of June 30, 2017 and December 31, 2016 were as follows (in thousands): Level 1 Level 2 Level 3 Total Carrying Value June 30, 2017 Assets: Cash, cash equivalents, restricted cash $ 2,851 $ - $ - $ 2,851 $ 2,851 Investment in equity securities - - 579 579 579 Total $ 2,851 $ - $ 579 $ 3,430 $ 3,430 Liabilities: Debt obligations $ - $ - $ 7,236 $ 7,236 $ 7,149 Total $ - $ - $ 7,236 $ 7,236 $ 7,149 December 31, 2016 Assets: Cash, cash equivalents, restricted cash $ 3,121 $ - $ - $ 3,121 $ 3,121 Investment in equity securities - - 579 579 579 Total $ 3,121 $ - $ 579 $ 3,700 $ 3,700 Liabilities: Debt obligations $ - $ - $ 7,354 $ 7,354 $ 7,311 Total $ - $ - $ 7,354 $ 7,354 $ 7,311

Basis of Presentation (Details

Basis of Presentation (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 29, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Aug. 04, 2017
Basis Of Presentation [Line Items]
Gain (Loss) on Extinguishment of Debt		$ 0	$ 0	$ 0	$ (108,000)
Warrants Issued With cashless exercise during period				25,000
Class of Warrant or Right, Outstanding						100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 2.20
Common Stock [Member]
Basis Of Presentation [Line Items]
Stock Issued During Period, Shares, Warrants Exercised						100,000
Notes Payable [Member]
Basis Of Presentation [Line Items]
Gain (Loss) on Extinguishment of Debt						$ 108,000
Warrants Not Settleable in Cash, Fair Value Disclosure						145,000
Debt Instrument, Unamortized Discount						80,000
Deferred Fees From Issuance Of Note						$ 28,000
Warrants Issued With cashless exercise during period				50,000
OR21 LLC [Member]
Basis Of Presentation [Line Items]
Equity Method Investment, Ownership Percentage		50.00%		50.00%
Architectural Design Company [Member]
Basis Of Presentation [Line Items]
Equity Method Investment, Ownership Percentage		50.00%		50.00%
Mevion Medical Systems Inc [Member]
Basis Of Presentation [Line Items]
Repayments of Notes Payable	$ 1,000,000
Mevion Medical Systems Inc [Member] | Subsequent Event [Member]
Basis Of Presentation [Line Items]
Prepaid Contract Expenses							$ 1,000,000

Per Share Amounts (Details)

Per Share Amounts (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Net income attributable to American Shared Hospital Services	$ 113,000	$ 93,000	$ 406,000	$ 144,000
Weighted average common shares for basic earnings per share	5,935,000	5,552,000	5,725,000	5,548,000
Diluted effect of stock options and restricted stock	208,000	16,000	196,000	16,000
Weighted average common shares for diluted earnings per share	6,143,000	5,568,000	5,921,000	5,564,000
Basic earnings per share	$ 0.02	$ 0.02	$ 0.07	$ 0.03
Diluted earnings per share	$ 0.02	$ 0.02	$ 0.07	$ 0.03

Per Share Amounts (Details Text

Per Share Amounts (Details Textual) - shares	3 Months Ended	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	605,000	627,000

Stock-based Compensation (Detai

Stock-based Compensation (Details) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Jun. 30, 2017USD ($)$ / sharesshares
Shareholders Equity [Line Items]
Number of Options, Outstanding Beginning Balance | shares	4,000
Number of Options, Granted | shares	21,000
Number of Options, Vested | shares	(13,000)
Number of Options, Forfeited | shares	0
Number of Options, Outstanding Ending Balance | shares	12,000
Weighted Average Grant-Date Fair Value, Outstanding Beginning Balance | $ / shares	$ 2.25
Weighted Average Grant-Date Fair Value, Granted | $ / shares	3.48
Weighted Average Grant-Date Fair Value, Vested | $ / shares	3.07
Weighted Average Grant-Date Fair Value, Forfeited | $ / shares	0
Weighted Average Grant-Date Fair Value, Outstanding Ending Balance | $ / shares	$ 3.54
Intrinsic Value, Outstanding, Outstanding Beginning Balance | $	$ 0
Intrinsic Value, Granted | $	0
Intrinsic Value, Vested | $	0
Intrinsic Value, Forfeited | $	0
Intrinsic Value, Outstanding, Outstanding Ending Balance | $	$ 4,000

Stock-based Compensation (Det21

Stock-based Compensation (Details 1) - Employee Stock Option [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Schedule Of Share Based Compensation Stock Options Activity [Line Items]
Number of Options, Beginning balance	625,000
Number of Options, Granted	14,000
Stock Options, Exercised	(4,000)
Stock Options, Forfeited	(23,000)
Number of Options, Ending balance	612,000	625,000
Stock Options, Exercisable	295,000
Weighted Average Exercise Price, Beginning balance	$ 2.85
Weighted Average Exercise Price, Granted	3.90
Weighted Average Exercise Price, Exercised	2.81
Weighted Average Exercise Price, Forfeited	2.82
Weighted Average Exercise Price, Ending balance	2.87	$ 2.85
Grant Date Weighted Average Exercise Price, Exercisable	$ 2.82
Weighted Average Remaining Contractual Life (Years), Balance	3 years 10 months 6 days	4 years 3 months
Weighted Average Remaining Contractual Life (Years), Exercisable	3 years 7 months 17 days

Stock-based Compensation (Det22

Stock-based Compensation (Details Textual) - USD ($)	Jan. 04, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2010
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share Based Compensation Expense		$ 50,000	$ 60,000	$ 100,000	$ 119,000
Incentive Compensation Plan [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance						1,630,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		358,000		358,000
Performance Share Award Agreement [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 542,000		$ 542,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	161,766

Investment in Equity Securiti23

Investment in Equity Securities (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Schedule of Cost-method Investments [Line Items]
Cost Method Investments	$ 579,000	$ 579,000
Mevion Medical Systems Inc [Member]
Schedule of Cost-method Investments [Line Items]
Cost Method Investments	$ 579,000
Cost Method Investments Ownership Percentage	0.46%

Fair Value of Financial Instr24

Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Assets, Carrying Value:
Cash, cash equivalents, restricted cash, Carrying Value	$ 2,851	$ 3,121
Investment in equity securities, Carrying Value	579	579
Total, Carrying Value	3,430	3,700
Liabilities, Carrying Value
Debt obligations, Carrying Value	7,149	7,311
Total, Carrying Value	7,149	7,311
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	2,851	3,121
Investment in equity securities, Fair Value	579	579
Total, Fair Value	3,430	3,700
Liabilities, Fair Value
Debt obligations, Fair Value	7,236	7,354
Total, Fair Value	7,236	7,354
Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	2,851	3,121
Investment in equity securities, Fair Value	0	0
Total, Fair Value	2,851	3,121
Liabilities, Fair Value
Debt obligations, Fair Value	0	0
Total, Fair Value	0	0
Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	0	0
Investment in equity securities, Fair Value	0	0
Total, Fair Value	0	0
Liabilities, Fair Value
Debt obligations, Fair Value	0	0
Total, Fair Value	0	0
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	0	0
Investment in equity securities, Fair Value	579	579
Total, Fair Value	579	579
Liabilities, Fair Value
Debt obligations, Fair Value	7,236	7,354
Total, Fair Value	$ 7,236	$ 7,354

Repurchase of Common Stock (Det

Repurchase of Common Stock (Details Textual) - shares	Jun. 30, 2017	Dec. 31, 2008
Equity, Class of Treasury Stock [Line Items]
Stock Repurchase Program, Number of Shares Authorized to be Repurchased		1,000,000
Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased	72,000